Xencor, Inc Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Xencor, Inc (XNCR) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $503.23 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $503.23M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $515.63M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $635.59M.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $625.32M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest as first filed |
|---|---|---|
| 2026-06-30 | $503.23M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $515.63M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $635.59M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $625.32M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $620.35M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $639.87M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $674.03M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $705.93M 10-Q · filed 2025-11-05 | $720.90M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $548.71M 10-Q · filed 2025-11-05 | $562.54M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $599.73M 10-Q · filed 2025-11-05 | $612.19M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $662.09M 10-K · filed 2026-02-25 | $669.13M 10-K · filed 2024-02-29 |
| 2023-09-30 | $669.01M 10-Q/A · filed 2025-02-24 | |
| 2023-06-30 | $678.88M 10-Q/A · filed 2025-02-24 | |
| 2023-03-31 | $683.58M 10-Q/A · filed 2025-02-24 | |
| 2022-12-31 | $727.50M 10-K · filed 2026-02-25 | |
| 2021-12-31 | $733.50M 10-K · filed 2025-02-27 | |
| 2020-12-31 | $572.44M 10-K/A · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |